Product name: Dabigatran etexilate mesylate
CAS: 872728-81-9
Assay: ≥98.5%
MF: C34H41N7O5.CH4O3S C8H15NO2
Appearance: White to off-white solid
Melting Point: 178~183°C
Dabigatran Etexilate Mesylate powder cas 872728-81-9 is used to prevent stroke and harmful blood clots (such as in your legs or lungs) if you have a certain type of irregular heartbeat (atrial fibrillation).
*The following content is generated by AI and is for reference only.
Dabigatran etexilate mesylate powder is a highly pure pharmaceutical intermediate and active research compound widely utilized in the field of anticoagulant therapy. Chemically, this substance serves as the prodrug form of dabigatran, which is a potent, direct thrombin inhibitor. The molecular formula for Dabigatran etexilate mesylate is C21H31N5O4·CH4O3S, reflecting its complex structure comprising the core dabigatran etexilate molecule paired with a methanesulfonate salt to enhance stability and solubility. Its corresponding CAS number is 690877-18-2, a unique identifier essential for precise chemical inventory management and regulatory compliance in global laboratories.
The primary utility of this powder lies in pharmacological research and drug development. Scientists employ it extensively to study the mechanism of action regarding coagulation pathways, specifically focusing on how direct thrombin inhibition prevents blood clot formation without relying on antithrombin III. As a critical precursor, it is used to synthesize the final medicinal product, Pradaxa (dabigatran etexilate), which is clinically approved for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for treating deep vein thrombosis and pulmonary embolism. Researchers utilize high-purity Dabigatran etexilate mesylate powder to conduct in vitro assays, establish dose-response curves, and validate new analytical methods for detecting thrombin inhibitors in biological samples.
In the manufacturing sector, this compound ensures the production of consistent and effective therapeutic agents. Its mesylate salt form offers superior physical properties compared to the free base, facilitating easier handling during the formulation process into capsules or tablets. While not intended for direct human consumption in raw powder form, its role in advancing cardiovascular medicine is indispensable. Strict quality control measures are applied to ensure the absence of impurities, guaranteeing safety and efficacy when converted into finished dosage forms. Consequently, Dabigatran etexilate mesylate powder remains a cornerstone material for academic institutions, biotechnology firms, and pharmaceutical manufacturers dedicated to improving patient outcomes through advanced anticoagulant strategies.